BCT

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

Retrieved on: 
Tuesday, April 9, 2024
HER2, ILD, CPI, Survival, Progression-free survival, Central nervous system, Patient, CNS, History, Death, Eribulin, Spacecraft, MD, CBR, TPC, EMBRACE, Life, BCT, AACR, TSX, Therapy, Breast cancer, Safety, Poster, CMO, PFS, ADC, PD-1, Pharmaceutical industry

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.

Key Points: 
  • “ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
  • To our knowledge, there are no effective treatment options in this patient population for whom the progression-free survival prognosis is only a few weeks.
  • BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
  • Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.

Koning Health Celebrates Milestone of 150,000 Scans Worldwide

Retrieved on: 
Wednesday, March 27, 2024
MRI, Radiology, Monroe Dunaway Anderson, Breast MRI, Health, Patient, Woman, BCT, Google Images, DBT, Physician, Medical imaging

NORCROSS, Ga., March 27, 2024 /PRNewswire/ -- Koning Health , leader in advanced medical imaging technology, is proud to announce a significant milestone in its journey to revolutionize diagnostic imaging.

Key Points: 
  • NORCROSS, Ga., March 27, 2024 /PRNewswire/ -- Koning Health , leader in advanced medical imaging technology, is proud to announce a significant milestone in its journey to revolutionize diagnostic imaging.
  • Since its inception, Koning has been at the forefront of medical imaging technology, continually pushing the boundaries of what is possible.
  • The completion of 150,000 scans is not just a number; it represents countless lives impacted, diagnoses clarified, and treatments optimized.
  • Experts are taking note of the capabilities presented with Koning Vera Breast CT, including physicians like Dr. David Bodne.

BCT-Bank of Charles Town Announces Alice Frazier Elected as Vice Chairman of ICBA

Retrieved on: 
Monday, March 18, 2024
Community, Federal Reserve Bank, Environment, Independent, ICBA, Education, Bank, Executive Committee, BCT, OTC, Fountain Trust, Policy, Virginia Association, Service network, Management

CHARLES TOWN, W.Va., March 18, 2024 /PRNewswire/ -- (OTC:PTBS) BCT-Bank of Charles Town, also known as The Community's Bank, is pleased to announce the Independent Community Bankers of America (ICBA) has elected Alice Frazier, BCT's President and CEO, as the ICBA Vice Chairman.

Key Points: 
  • CHARLES TOWN, W.Va., March 18, 2024 /PRNewswire/ -- (OTC:PTBS) BCT-Bank of Charles Town, also known as The Community's Bank, is pleased to announce the Independent Community Bankers of America (ICBA) has elected Alice Frazier, BCT's President and CEO, as the ICBA Vice Chairman.
  • "I'm deeply honored to champion the cause of our nation's community banks in my role as ICBA vice chairman," Frazier said.
  • "As relationship lenders with deep community ties, our success is intricately connected to the prosperity of those we serve.
  • She is a member of the ICBA Executive Committee and board of directors and is vice chairman of the Federal Delegate Board.

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Retrieved on: 
Thursday, March 7, 2024
Master of Science, Breast cancer, BCT, Division, CMO, Doctor of Philosophy, MD, University, Quality of life, TSX, Letter, Vaccine, Breast, MD Anderson Cancer Center, Cancer, Therapy, Associate professor, Patient, Survival, Disease, Prostate cancer, Pharmaceutical industry

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell

Key Points: 
  • Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell
    PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.
  • “We are ecstatic about working with the team led by Dr. Pohlmann,” stated Dr. Williams, BriaCell’s President & CEO.
  • “We strongly believe in the therapeutic potential of our novel personalized next-generation vaccine platform and this agreement will be invaluable to us as we advance the clinical development of our off-the-shelf therapies to those cancer patients with persistent unmet medical needs.”
    “Through this agreement, we expect to further our understanding of our novel immunotherapy’s mechanism of action and its use in breast and prostate cancer patients,” stated Dr. Giuseppe Del Priore, BriaCell’s CMO.
  • “Our shared goal is to improve the survival and quality of life in cancer patients who are fighting a disease with a poor prognosis and a short life expectancy.”

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

Retrieved on: 
Wednesday, March 6, 2024
TSX, BCT, Therapy, AACR

PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10 at San Diego Convention Center, San Diego, CA.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10 at San Diego Convention Center, San Diego, CA.
  • The details are listed below.

Boldyn Networks Provides Base-Wide Connectivity for U.S. Army's Fort Jackson

Retrieved on: 
Thursday, February 22, 2024
BCT, Woman, Quality of life, Army, Department of Defence, Telecommunications, Housing, Mobile phone

COLUMBIA, S.C., Feb. 22, 2024 /PRNewswire/ -- Boldyn Networks (Boldyn), a leading neutral host telecommunications infrastructure provider in the United States and globally, announced the completion of its connectivity deployment at Fort Jackson Army base in Columbia, South Carolina. This best-in-class wireless network delivers base-wide connectivity to the country's biggest and most active U.S. Army Basic Combat Training (BCT) installation.

Key Points: 
  • This best-in-class wireless network delivers base-wide connectivity to the country's biggest and most active U.S. Army Basic Combat Training (BCT) installation.
  • "As we look to enhance our operations at Fort Jackson and bolster our communications, secure and reliable coverage is paramount.
  • "By partnering with Boldyn, Fort Jackson is now equipped with state-of-the-art infrastructure, making it one of the most technologically advanced bases in the country."
  • "Boldyn's network deployment at Fort Jackson brings industry-leading, fast, reliable connectivity across the base and all its facilities," said Christos Karmis, Boldyn's U.S. CEO.

Bain Capital Real Estate and Cherry Tree Capital Partners Form Joint Venture to Develop Rental Townhome Communities in Southern California

Retrieved on: 
Tuesday, February 13, 2024
Finance, Professional Services, Residential Building & Real Estate, Construction & Property, Urban Planning, BCT, KB Home, Sale, School, Irvine Company, Housing, Head, Partnership, Real estate

Bain Capital Real Estate and Cherry Tree Capital Partners today announced the formation of BCT Development, a strategic joint venture focused on the ground-up development of premier rental townhome communities throughout Southern California.

Key Points: 
  • Bain Capital Real Estate and Cherry Tree Capital Partners today announced the formation of BCT Development, a strategic joint venture focused on the ground-up development of premier rental townhome communities throughout Southern California.
  • The joint venture launches with the objective of deploying several hundred million dollars of gross capital over the next several years.
  • “Bain Capital Real Estate has a long-standing reputation as a thoughtful, thematic investor who shares our conviction in the multifamily housing space.
  • The Cherry Tree Capital Partners team also includes Principals Austin Maleki, Mike Wu, and John Bosco.

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Retrieved on: 
Wednesday, February 7, 2024
Survival, Breast cancer, PFS, Literature, Patient, Pain, TSX, ADC, Therapy, Quality of life, HLA, Spacecraft, Liver disease, Liver, BCT, ILD, Pharmaceutical industry

exhibited clinical outcomes) Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen – the same formulation being used in BriaCell’s open pivotal Phase 3 study.

Key Points: 
  • exhibited clinical outcomes) Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen – the same formulation being used in BriaCell’s open pivotal Phase 3 study.
  • Additionally, a disease control rate of 50% was reported in similarly treated evaluable patients who had failed prior antibody-drug conjugate (ADC) therapy.
  • “This data provides further encouragement to us as we continue our pivotal Phase 3 study enrollment.
  • No cases of Interstitial Lung Disease (ILD) with Bria-IMT™ (a well-documented serious side effect of ADCs) reported in this group of patients.

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Retrieved on: 
Tuesday, February 6, 2024
Prostate cancer, Investigational New Drug, Cytokine, Immunotherapy, SITC, Clinical trial, NK, Society, Patient, IND, Good, Death, TSX, Allele, NKT, Therapy, Vaccine, Good manufacturing practice, HLA, Cancer, GMP, BCT

We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Key Points: 
  • We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application.
  • BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines.
  • According to 2024 Cancer Facts & Figures , prostate cancer is projected to be the most common cancer among men in 2024.

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Retrieved on: 
Wednesday, January 31, 2024
TSX, MNP, Therapy, Indian stock exchange, MNP LLP, Remuneration, BCT, Shareholder

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2023 held on January 30, 2024 (the “Meeting”).

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2023 held on January 30, 2024 (the “Meeting”).
  • A total of 5,375,071 common shares of the Company (the “Common Shares”) were voted, representing 33.63% of the Company’s issued and outstanding Common Shares.
  • Gross, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg as directors of the Company.
  • A total of 5,375,071 common shares were voted in connection with the election of the directors as follows: